Challenges of pancreatic cancer

Cancer Journal (United States)

Volumn 21, Issue 3, 2015, Pages 188-193

  Dimastromatteo, Julien ^a   Houghton, Jacob L ^b   Lewis, Jason S ^b   Kelly, Kimberly A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Molecular imaging; molecular imaging agents; pancreatic cancer

Indexed keywords

CATHEPSIN E; CLAUDIN 4; DIFFERENTIATION ANTIGEN; OSTEONECTIN; PLECTIN 1; SCAFFOLD PROTEIN; THYMOCYTE DIFFERENTIATION ANTIGEN 1; TUMOR MARKER; UNCLASSIFIED DRUG;

CELL POPULATION; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; MOLECULAR IMAGING; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STROMA CELL; ULTRASOUND; BLOOD; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; PANCREAS TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; ENDOTHELIAL CELLS; EPITHELIAL CELLS; HUMANS; MOLECULAR IMAGING; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHY; STROMAL CELLS;

EID: 84930589944     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000109     Document Type: Review

References (44)

1. Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer. 1985;56:397-402.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10-15.
4. Fröhlich A, Diederichs CG, Staib L, et al. Detection of liver metastases from pancreatic cancer using FDG PET. J NuclMed. 1999;40:250-255.
5. Higashi T, Saga T, Nakamoto Y, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)-usefulness and limitations in "clinical reality". Ann Nucl Med. 2003;17:261-279.
6. Murakami K. FDG-PET for hepatobiliary and pancreatic cancer: advances and current limitations. World J Clin Oncol. 2011;2:229-236.
7. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis andmanagement of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119.
8. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270.
9. Kim H-R, Lee C-H, Kim YW, et al. Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med. 2009;47:750-754.
10. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J ClinOncol. 2005;23:1011-1027.
11. Longo R, Cacciamani F, Naso G, et al. Pancreatic cancer: from molecular signature to target therapy. Crit Rev Oncol Hematol. 2008;68:197-211.
12. KorcM. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer. 2003;2:8.
13. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res. 2006;12:2197-2207.
14. Spano J-P, Chodkiewicz C, Maurel J, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008;371: 2101-2108.
15. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997;3:1309-1316.
16. Büchler P, Reber HA, Roth MM, et al. Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia. 2007;9:119-127.
17. Higgins KJ, AbdelrahimM, Liu S, et al. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun. 2006;345:292-301.
18. Luo J, Guo P, Matsuda K, et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer. 2001;92:361-369.
19. Shi Q, Le X, Abbruzzese JL, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 2001;61:4143-4154.
20. Korpanty G, Carbon JG, Grayburn PA, et al. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res. 2007;13:323-330.
21. Deshpande N, Ren Y, Foygel K, et al. Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. Radiology. 2011;258:804-811.
22. Foygel K, Wang H, Machtaler S, et al. Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. Gastroenterology. 2013;145:885.e3-894.e3.
23. Cocco E, Casagrande F, Bellone S, et al. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer. 2010;10:349.
24. Boylan KLM, Misemer B, De Rycke MS, et al. Claudin 4 Is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation. Int J Mol Sci. 2011;12:1334-1358.
25. Kojima T, Kyuno D, Sawada N. Targeting claudin-4 in human pancreatic cancer. Expert Opin Ther Targets. 2012;16:881-887.
26. Neesse A, Hahnenkamp A, Griesmann H, et al. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut. 2013;62: 1034-1043.
27. Foss CA, Fox JJ, Feldmann G, et al. Radiolabeled anti-claudin 4 and antiprostate stem cell antigen: initial imaging in experimental models of pancreatic cancer. Mol Imaging. 2007;6:131-139.
28. Kelly KA, BardeesyN, Anbazhagan R, et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med. 2008;5:e85.
29. Shin SJ, Smith JA, Rezniczek GA, et al. Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer. Proc Natl Acad Sci. 2013;110:19414-19419.
30. Coté GA, Smith J, Sherman S, et al. Technologies for imaging the normal and diseased pancreas. Gastroenterology. 2013;144:1262.e1-1271.e1.
31. Bausch D, Thomas S, Mino-Kenudson M, et al. Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res. 2011;17:302-309.
32. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol. 2008;1:306-316.
33. Cruz-Monserrate Z, Abd-Elgaliel WR, Grote T, et al. Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Gut. 2012;61:1315-1322.
34. Lane TF, Sage EH. The biology of SPARC, a protein that modulates cellmatrix interactions. FASEB J. 1994;8:163-173.
35. Clark CJ, Sage EH. A prototypic matricellular protein in the tumor microenvironment-where there's SPARC, there's fire. J Cell Biochem. 2008;104:721-732.
36. Thomas S, Waterman P, Chen S, et al. Development of secreted protein and acidic and rich in cysteine (SPARC) targeted nanoparticles for the prognostic molecular imaging of metastatic prostate cancer. J Nanomed Nanotechnol. 2011;2.
37. Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serumCA19.9 in pancreatic cancer. AnnOncol. 2012;23:1713-1722.
38. Sugiura T, Uesaka K, Kanemoto H, et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16: 977-985.
39. Kannagi R, Izawa M, Koike T, et al. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 2004;95:377-384.
40. Sawada R, Sun S-M, Wu X, et al. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res. 2011;17:1024-1032.
41. Viola-Villegas NT, Rice SL, Carlin S, et al. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J NuclMed. 2013;54:1876-1882.
42. Rochefort MM, Girgis MD, Knowles SM, et al. A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. Mol Imaging Biol. 2014;16:721-729.
43. Girgis MD, Kenanova V, Olafsen T, et al. Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res. 2011;170:169-178.
44. Girgis MD, Federman N, RochefortMM, et al. An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. J Surg Res. 2013;185:45-55.